<form id="lwufo"><acronym id="lwufo"></acronym></form>
          Log in
          E-mail
          Password
          Remember
          Forgot password ?
          Become a member for free
          Sign up
          Sign up
          New member
          Sign up for FREE
          New customer
          Discover our services
          Settings
          Settings
          Dynamic quotes 
          OFFON

          MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

          MERCK KGAA

          (MRK)
            Report
          Real-time Estimate Quote. Real-time Estimate Tradegate - 09/16 03:57:40 pm
          123.825 EUR   +1.00%
          01:22pMERCK KGAA : Bernstein remains Neutral
          MD
          12:50pMERCK : says it has overcome production shortages in vaccine materials
          RE
          05:21aMERCK KGAA : JP Morgan sticks Neutral
          MD
          SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
          SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

          Merck KGaA says profit could slip as fertility treatments shunned

          share with twitter share with LinkedIn share with facebook
          05/14/2020 | 02:41am EDT
          A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

          By Ludwig Burger

          Merck KGaA said a slight decline in operating earnings was on the cards this year as the coronavirus pandemic weighs on demand for chemicals in TV screens and is putting couples off seeking the German group's fertility treatments.

          Earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, would likely be between 4.35 billion euros ($4.70 billion) and 4.85 billion euros, compared with 4.39 billion last year, it said on Thursday.

          First-quarter adjusted EBITDA gained 27% to 1.2 billion euros, the healthcare and chemicals company said, surpassing an average analyst estimate of 1.1 billion euros in a Refinitiv poll.

          Chinese patients sought larger prescriptions of Merck's older diabetes and heart drugs for less frequent hospital visits, offsetting lower sales of fertility drugs.

          Results in the January-to-March period were further bolstered by the addition of electronics materials maker Versum, which the company acquired in October 2019.

          Merck said it expected Versum's chemicals that are used in semiconductors to see strong growth for the remainder of the year despite the coronavirus.

          "The Covid-19 crisis... only had a moderate impact in the first quarter of 2020. However, the company expects the effects to amplify in the coming months," it said.

          Merck had previously banked on the pandemic peaking in the first quarter and subsiding during the second, raising the prospect of strong EBITDA growth in 2020.

          But it is now bracing for the crisis to prevail during the entire year, posing a significant burden to the economy.

          Many fertility clinics across the world had closed in response to the virus outbreak and are now reopening only at reduced capacity, Merck said, adding that it does not expect a catch-up effect until after an economic recovery.

          (Reporting by Ludwig Burger; Editing by Michelle Martin)

          Stocks mentioned in the article
          ChangeLast1st jan.
          AT HOME GROUP INC. -4.05% 15.135 Delayed Quote.187.27%
          JUST GROUP PLC -1.89% 49.94 Delayed Quote.-35.57%
          MERCK & CO., INC. 1.98% 85.88 Delayed Quote.-7.41%
          MERCK KGAA 1.39% 124.3 Delayed Quote.16.37%
          PROSPECT CO., LTD. -2.63% 37 End-of-day quote.27.59%
          THE NEW HOME COMPANY INC. 3.20% 4.19 Delayed Quote.-12.88%
          WILL GROUP, INC. 0.86% 935 End-of-day quote.-25.32%
          WORLD CO., LTD. 3.45% 1470 End-of-day quote.-45.37%
          share with twitter share with LinkedIn share with facebook
          All news about MERCK KGAA
          01:22pMERCK KGAA : Bernstein remains Neutral
          MD
          12:50pMERCK : says it has overcome production shortages in vaccine materials
          RE
          05:21aMERCK KGAA : JP Morgan sticks Neutral
          MD
          05:18aMERCK KGAA : Goldman Sachs reiterates its Sell rating
          MD
          02:45aMERCK : Confirms 2020 Outlook; Prioritizes Lower Debt
          DJ
          02:41aMERCK : Germany's Merck says it will focus on smaller takeovers
          RE
          09/15MERCK KGAA : JP Morgan remains Neutral
          MD
          09/14MERCK KGAA : Darmstadt, Germany Announces Positive Phase II Results for Investig..
          AQ
          09/14MERCK KGAA : Morgan Stanley remains Neutral
          MD
          09/13MERCK : Darmstadt, Germany, Advances Oncology Portfolio and Pipeline with New an..
          PU
          More news
          Financials
          Sales 2020 17 299 M 20 451 M 20 451 M
          Net income 2020 1 684 M 1 991 M 1 991 M
          Net Debt 2020 10 660 M 12 603 M 12 603 M
          P/E ratio 2020 30,9x
          Yield 2020 1,10%
          Capitalization 53 304 M 63 134 M 63 018 M
          EV / Sales 2020 3,70x
          EV / Sales 2021 3,42x
          Nbr of Employees 57 523
          Free-Float 29,7%
          Chart MERCK KGAA
          Duration : Period :
          Merck KGaA Technical Analysis Chart | MarketScreener
          Full-screen chart
          Technical analysis trends MERCK KGAA
          Short TermMid-TermLong Term
          TrendsBullishBullishNeutral
          Income Statement Evolution
          Consensus
          Sell
          Buy
          Mean consensus OUTPERFORM
          Number of Analysts 22
          Average target price 118,95 €
          Last Close Price 122,60 €
          Spread / Highest target 22,3%
          Spread / Average Target -2,98%
          Spread / Lowest Target -25,0%
          EPS Revisions
          Managers
          NameTitle
          Stefan Oschmann Chairman-Executive Board & CEO
          Wolfgang Heinz B點hele Chairman-Supervisory Board
          Marcus Kuhnert Chief Financial Officer
          Christian Raabe Independent Member-Supervisory Board
          Edeltraud Gl鋘zer Independent Member-Supervisory Board
          Sector and Competitors
          1st jan.Capitalization (M$)
          MERCK KGAA16.37%63 149
          ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD132.17%22 259
          KYOWA KIRIN CO., LTD.11.74%14 499
          BETTA PHARMACEUTICALS CO., LTD.73.04%6 797
          YUHAN CORPORATION44.61%3 646
          RECIPHARM AB (PUBL)19.15%1 793
          官方真人棋牌游戏平台